Back to top
more

4D Molecular Therapeutics (FDMT)

(Real Time Quote from BATS)

$7.87 USD

7.87
369,197

-0.20 (-2.48%)

Updated Nov 12, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0% and 9.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of 21.74% and 55.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?

by Zacks Equity Research

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Wall Street Analysts Think 4D Molecular Therapeutics (FDMT) Could Surge 225.1%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for 4D Molecular Therapeutics (FDMT) points to a 225.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 12.50% and 99.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CARISMA THERAP (CARM) delivered earnings and revenue surprises of 25% and 151.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -9.09% and 3.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -1.19% and 1.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -13.24% and 100.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?

by Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy

by Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of 0% and 83.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 6.67% and 8.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics Inc. (FHTX) Surges 12.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of 0% and 79.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 60% and 27.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 13.21% and 2.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -2.44% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?